List of works - Marion Wiesmann

A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues

scientific article published on 21 December 2021

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

scientific article published on 12 May 2015

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

scientific article

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

scientific article

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia

scientific article published in July 2005

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

scientific article

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

scientific article published on 17 November 2016

Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

scientific article published on 5 April 2006

Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases

scientific article published on 30 January 2006

Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors

scientific article

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

scientific article published on 22 August 2018

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

scientific article published on 19 October 2015

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

scientific article

Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors ⬇️

scientific article published on October 13, 2010

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

scientific article published on 26 August 2011

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

scientific article

Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics

scientific article published on May 2011

Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite

scientific article published on 2 September 2014

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

scientific article published on 6 March 2017

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib ⬇️

scientific article published on August 14, 2010

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

scientific article

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

scientific article published on April 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

scientific article published on 11 July 2016

beta-Catenin regulates vascular endothelial growth factor expression in colon cancer

scientific article

List of works by Marion Wiesmann

A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases

Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors ⬇️

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics

Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib ⬇️

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

beta-Catenin regulates vascular endothelial growth factor expression in colon cancer